COMMUNIQUÉS West-GlobeNewswire

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
08/04/2025
Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq [...]
Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health
08/04/2025
WASHINGTON, D.C., April 08, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious [...]
Hydreight Technologies Partners with Renowned Endocrinologist Dr. Franklin Joseph to Bring Globally Successful Weight Loss Brand to the U.S. via VSDHOne Platform
08/04/2025
Partnership combines Dr. Frank’s Proven GLP-1 Weight-Loss Method with Hydreight’s Innovative Telehealth Platform, Targeting the U.S. Weight Loss Market VANCOUVER, British Columbia and LAS VEGAS, April 08, 2025 (GLOBE [...]
SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)
08/04/2025
SANUWAVE is pleased to announce preliminary revenues of $9.1 million to $9.3 million for the first quarter ended March 31, 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 revenue [...]
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics
08/04/2025
Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technology HOUSTON, April 08, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. ( [...]
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
08/04/2025
CINCINNATI, April 08, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) (formerly Blue Water Biotech Inc.) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held [...]
Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain
08/04/2025
Company on track to commence U.S. clinical studies in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX, April 08, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or [...]
Biotricity Recognized by Financial Times as One of 2025’s Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed
08/04/2025
REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions [...]
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
08/04/2025
CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and [...]
OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ System
08/04/2025
WARSAW, Ind., April 08, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery
08/04/2025
DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.
08/04/2025
TAMPA, FL, April 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) , a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value [...]
Ocugen to Present at the 2025 Cell & Gene Meeting on the Med
08/04/2025
MALVERN, Pa., April 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri [...]
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
08/04/2025
NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “ [...]
Lantern Names CTO, deepens investment in Specialty Care Platform
08/04/2025
Former Accolade Executive brings scale and innovation to market leader DALLAS, April 08, 2025 (GLOBE NEWSWIRE) -- Lantern , the Specialty Care Platform connecting 6 million members with the best surgery, cancer and [...]
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
08/04/2025
First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is expected to complete [...]
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies
08/04/2025
BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma
08/04/2025
clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission SEATTLE, April 08, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage [...]
Vivex Biologics, Inc. Provides Enrollment Update for its ASCEND Study Examining Whether Supplementing Discs with VIA Disc NP™ Reduces Pain and/or Improves Function in Patients with Symptomatic Disc Degeneration
08/04/2025
Data readout expected in Q1 2026 MIAMI, April 08, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced the company has enrolled 50% of the patients [...]

Pages